Phase II Evaluation Of GROC (Gemcitabine- Rituximab-Oxaliplatin Combination) Given Every 14 Days For The Treatment Of Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma
- Patients with refractory or relapsed aggressive non-Hodgkin's Lymphoma. The
definition of refractory includes patients who either did not respond to prior
therapy or those whose best response was a PR after at least 4 courses of
chemotherapy. Aggressive histologies include follicular large cell, diffuse large
cell, peripheral T cell, transformed lymphomas, Lymphoblastic lymphomas, Burkitt and
Burkitt like lymphomas.
- Histologic or cytological confirmation of refractory or relapsed aggressive
non-Hodgkin's Lymphoma is desirable but not mandatory and will be left to the
discretion of the investigator.
- Must have measurable or evaluable disease.
- No more than 4 previous regimens of chemotherapy will be allowed, including stem cell
or bone marrow transplant.
- Patients must be more than 18 years old.
- No evidence of grade 3 or more neurosensory or neuromotor dysfunction (see appendix-
- Written Consent
- Those patients who have previously received a platinum or nucleoside
analogue-containing regimen are eligible.
- Patients who are candidates for stem cell or marrow transplant will be included
- Patients with a previous or concurrent history of cancer with the exception of:
1-treated carcinoma in situ of cervix or breast. 2- treated squamous or basal cell
skin cancer, or 3- any other surgically cured malignancy from which the patient has
been disease free for at least 5 years.
- HIV positive patients and those with Hepatitis B or C will be excluded from this
- Patients with severe neuropathy will be excluded.
- Chemotherapy or Radiotherapy within the previous 3 weeks prior to entering study.